Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease

Journal of Neurology

Volumn 251, Issue 5, 2004, Pages 529-536

  Girot, Marie ^a   Deplanque, Dominique ^a   Pasquier, Florence ^a   Destée, Alain ^a   Leys, Didier ^a  

^a UNIV LILLE   (France)

Author keywords

Angina pectoris; Myocardial infarction; Prevention; Stroke; TIA

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANAMNESIS; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; EUROPE; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SMOKING CESSATION; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BRAIN ISCHEMIA; CHOLESTEROL; CORONARY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 2542456780     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0357-8     Document Type: Article

References (39)

1. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A (1994) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90:583-612
2. Hankey GJ, Warlow CP (1999) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354:1457-1463
3. Rokey R, Rolak LA, Harati Y, Kutka N, Verani MS (1984) Coronary artery disease in patients with cerebrovascular disease: a prospective study. Ann Neurol 16:50-53
4. Chimowitz MI, Poole RM, Starling MR, Schwaiger M, Gross MD (1997) Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. Stroke 28:941-945
5. Kannel WB, Wolf PA, Verter J (1983) Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 250:2942-2946
6. Tanne D, Shotan A, Goldbourt U, Haim M, Boyko V, Adler Y, Mandelzweig L, Behar S (2002) Severity of angina pectoris and risk of ischemic stroke. Stroke 33:245-250
7. Bogousslavsky J, Kaste M, Skyhoj Olsen T, Hacke W, Orgogozo JM (2000) Risk factors and stroke prevention. European Stroke Initiative (EUSI). Cerebrovasc Dis 3(10):12-21
8. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K (1998) Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press 7:262-269
9. st century. Arch Intern Med 157:1177-1184
10. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
11. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041
12. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B (1994) Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056-2069
13. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, Werns S, Kern M, Plotkin D, Shih WJ, Mitchel Y, Ganz P (2000) Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102:846-851
14. Amarenco P (2001) Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57:35-44
15. Leys D, Deplanque D, Mounier-Vehier C, Mackowiak-Cordoliani M-A, Lucas C, Bordet R (2002) Stroke prevention: management of modifiable risk factors. J Neurol 249:507-517
16. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (syst-eur) study. Arch Intern Med 162:2046-2052
17. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
18. EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18:1569-1582
19. EUROASPIRE I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357:995-1001
20. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, Leys D (1999) Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 82:563-566
21. Redfern J, McKevitt C, Dundas R, Rudd AG, Wolfe CD (2000) Behavioral risk factor prevalence and lifestyle change after stroke: a prospective study. Stroke 31:1877-1881
22. Qureshi AI, Suri MF, Guterman LR, Hopkins LN (2001) Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 16:1621-1628
23. Special report from the National of Neurological Disorders and Stroke (1990) Classification of cerebrovascular diseases III. Stroke 21:637-676
24. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE (1984) International diagnosis criteria for acute myocardial infarction and acute stroke. Am Heart J 108:150-158
25. Campeau L (1976) Grading of angina pectoris. Circulation 54:522-523
26. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni Mhurchu C, Clark T (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009-1060
27. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106
28. Antiplatelet Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
29. The Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325:1261-1266
30. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
31. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1:1215-1220
32. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321:501-507
33. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13
34. Hennekens CH, Dyken ML, Fuster V (1997) Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American heart Association. Circulation 21:2751-2753
35. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ (2000) Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 36:699-705
36. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316:823-828
37. Wannamethee G, Shaper AG (1992) Physical activity and stroke in British middle aged men. BMJ 304:597-601
38. MacKenzie TD, Bartecchi CE, Schrier RW (1994) The human costs of tobacco use. N Engl J Med 33:975-980
39. Leys D, Bandu L, Hénon H, Lucas C, Mounier-Vehier F, Rondepierre P, Godefroy O (2002) Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology 59:26-33